Sika Raises 2026 Sales Outlook After Strong First-Half Results Beat Expectations 
Zhongji Innolight Raises $6.8 Billion in Hong Kong IPO as AI Demand Fuels Growth 
Galp Shares Fall After Q2 EBITDA Miss Despite Profit Beat and Higher Dividend 
Intel Stock Slips After Earnings Rally Despite Strong AI-Driven Revenue Growth 
Coca-Cola Raises Diet Coke Prices in India as Iran Conflict Disrupts Can Supply 
Tech Stock Positioning Nears Neutral as Investor Rotation Enters Final Phase, Deutsche Bank Says 
SpaceX Stock Slump Wipes Out Nearly $700 Billion From Elon Musk’s Paper Wealth 
Barclays Q2 Profit Beats Forecasts as Investment Banking Strength Offsets Higher Costs 
CATL Shares Jump as $5.6 Billion Buyback Signals Confidence in Long-Term Growth 
Brown-Forman Rejects Sazerac’s $15 Billion Takeover Bid as Family Backs Independence 
Unilever Raises 2026 Sales Outlook After Strong Q2 Volume Growth 
Stellantis Sells Free2move Car-Sharing Business to Mutares to Strengthen Core Auto Strategy 
Zabka Shares Drop 10% as Seven & i Abandons Investment Plans 
Nvidia Eyes $250B Guarantee for OpenAI’s Massive Ohio AI Data Center Project 
SAP Beats Q2 Revenue Estimates as Cloud Backlog and Business AI Demand Drive Growth. 
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
India’s Sun Pharmaceutical Industries (NSE: SUN) has announced a major acquisition, agreeing to purchase U.S.-based Organon & Co (NYSE: OGN) in an all-cash deal valued at approximately $11.75 billion. The move marks a significant step in Sun Pharma’s strategy to expand its global presence and strengthen its position in key pharmaceutical segments, including women’s health, branded generics, innovative medicines, and biosimilars.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash. This acquisition is expected to significantly enhance Sun Pharma’s product portfolio by adding more than 70 established and innovative medicines across women’s health and general therapeutic areas. Organon’s strong footprint in over 140 international markets will also provide Sun Pharma with broader geographic reach and improved market penetration.
Organon, which was spun off from Merck (NYSE: MRK) in 2021, has demonstrated solid financial performance. The company reported revenue of $6.2 billion and adjusted EBITDA of $1.9 billion for 2025, making it an attractive target for expansion-focused pharmaceutical companies. By integrating Organon’s assets, Sun Pharma aims to accelerate growth and diversify its revenue streams.
Following the completion of the deal, the combined entity is projected to generate pro forma revenue of around $12.4 billion. This would position Sun Pharma among the top 25 global pharmaceutical companies. Additionally, the acquisition is expected to establish Sun Pharma as a top-three player in the global women’s health market and the seventh-largest company in the biosimilars segment.
Sun Pharma plans to finance the transaction through a combination of internal cash reserves and committed bank financing. The deal has already received approval from both companies’ boards and is expected to close in early 2027, pending regulatory clearances and shareholder approvals. This strategic acquisition underscores Sun Pharma’s ambition to become a leading global pharmaceutical powerhouse while expanding its influence in high-growth therapeutic areas.
